Hongzhi Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongzhi Zeng has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Xue Gao
Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, USA.
5 shared publications - Qichen Yuan
Department of Chemical and Biomolecular Engineering, Rice University, Houston, USA
3 shared publications - Advaith Peddi
Department of BioSciences, Rice University, Houston, USA
2 shared publications Ananya Lingineni
Department of Bioengineering, Rice University, Houston, TX 77005, USA
2 shared publicationsBoyang Zhang
Department of Bioengineering, Rice University, Houston, USA
2 shared publicationsEmmanuel C. Osikpa
Department of Chemical and Biomolecular Engineering, Rice University, Houston, USA
2 shared publications
Latest Publications
- 23 June 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (12) , 1938-1947
A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising source of new pharmaceuticals, yet the therapeutic potential of fungal RiPPs remains largely underexplored. Here we report asperigimycins as a distinct class of fungal RiPPs, featuring a unique heptacyclic scaffold consisting of a benzofuranoindoline core and three additional macrocycles, primarily assembled by six distinct fungi-specific DUF3328 oxidases. Inspired by the enhancement of anticancer activity through the N-terminal pyroglutamate in naturally occurring asperigimycins C and D, we chemically modify the inactive asperigimycin B with a series of lipid substitutions at its N-terminus. A derivative with a C-11 linear fatty acid, 2-L6, achieves nanomolar anticancer potency comparable to that of clinically approved antileukemia drugs. High-throughput CRISPR screening identifies the SLC46A3 transporter as a critical factor mediating 2-L6 cellular uptake into human cells. Our findings highlight the promise of engineering asperigimycins as therapeutic leads for cancer treatment.
- 23 June 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (12) , 1938-1947
A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising source of new pharmaceuticals, yet the therapeutic potential of fungal RiPPs remains largely underexplored. Here we report asperigimycins as a distinct class of fungal RiPPs, featuring a unique heptacyclic scaffold consisting of a benzofuranoindoline core and three additional macrocycles, primarily assembled by six distinct fungi-specific DUF3328 oxidases. Inspired by the enhancement of anticancer activity through the N-terminal pyroglutamate in naturally occurring asperigimycins C and D, we chemically modify the inactive asperigimycin B with a series of lipid substitutions at its N-terminus. A derivative with a C-11 linear fatty acid, 2-L6, achieves nanomolar anticancer potency comparable to that of clinically approved antileukemia drugs. High-throughput CRISPR screening identifies the SLC46A3 transporter as a critical factor mediating 2-L6 cellular uptake into human cells. Our findings highlight the promise of engineering asperigimycins as therapeutic leads for cancer treatment.
- Open Access
- 11 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Author Correction: Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
- 11 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Open AccessAuthor Correction: Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
- Open Access
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
Programmable and modular systems capable of orthogonal genomic and transcriptomic perturbations are crucial for biological research and treating human genetic diseases. Here, we present the minimal versatile genetic perturbation technology (mvGPT), a flexible toolkit designed for simultaneous and orthogonal gene editing, activation, and repression in human cells. The mvGPT combines an engineered compact prime editor (PE), a fusion activator MS2–p65–HSF1 (MPH), and a drive-and-process multiplex array that produces RNAs tailored to different types of genetic perturbation. mvGPT can precisely edit human genome via PE coupled with a prime editing guide RNA and a nicking guide RNA, activate endogenous gene expression using PE with a truncated single guide RNA containing MPH-recruiting MS2 aptamers, and silence endogenous gene expression via RNA interference with a short-hairpin RNA. We showcase the versatility of mvGPT by simultaneously correcting a c.3207C>A mutation in the ATP7B gene linked to Wilson’s disease, upregulating the PDX1 gene expression to potentially treat Type I diabetes, and suppressing the TTR gene to manage transthyretin amyloidosis. In addition to plasmid delivery, we successfully utilize various methods to deliver the mvGPT payload, demonstrating its potential for future in vivo applications.
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Open AccessOrthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
Programmable and modular systems capable of orthogonal genomic and transcriptomic perturbations are crucial for biological research and treating human genetic diseases. Here, we present the minimal versatile genetic perturbation technology (mvGPT), a flexible toolkit designed for simultaneous and orthogonal gene editing, activation, and repression in human cells. The mvGPT combines an engineered compact prime editor (PE), a fusion activator MS2–p65–HSF1 (MPH), and a drive-and-process multiplex array that produces RNAs tailored to different types of genetic perturbation. mvGPT can precisely edit human genome via PE coupled with a prime editing guide RNA and a nicking guide RNA, activate endogenous gene expression using PE with a truncated single guide RNA containing MPH-recruiting MS2 aptamers, and silence endogenous gene expression via RNA interference with a short-hairpin RNA. We showcase the versatility of mvGPT by simultaneously correcting a c.3207C>A mutation in the ATP7B gene linked to Wilson’s disease, upregulating the PDX1 gene expression to potentially treat Type I diabetes, and suppressing the TTR gene to manage transthyretin amyloidosis. In addition to plasmid delivery, we successfully utilize various methods to deliver the mvGPT payload, demonstrating its potential for future in vivo applications.
- 7 February 2024
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 86, 103071
Recent advances in prime editing technologies and their promises for therapeutic applications
- 7 February 2024
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 86, 103071
Recent advances in prime editing technologies and their promises for therapeutic applications
- Open Access
- 11 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
A split and inducible adenine base editor for precise in vivo base editing
DNA base editors use deaminases fused to a programmable DNA-binding protein for targeted nucleotide conversion. However, the most widely used TadA deaminases lack post-translational control in living cells. Here, we present a split adenine base editor (sABE) that utilizes chemically induced dimerization (CID) to control the catalytic activity of the deoxyadenosine deaminase TadA-8e. sABE shows high on-target editing activity comparable to the original ABE with TadA-8e (ABE8e) upon rapamycin induction while maintaining low background activity without induction. Importantly, sABE exhibits a narrower activity window on DNA and higher precision than ABE8e, with an improved single-to-double ratio of adenine editing and reduced genomic and transcriptomic off-target effects. sABE can achieve gene knockout through multiplex splice donor disruption in human cells. Furthermore, when delivered via dual adeno-associated virus vectors, sABE can efficiently convert a single A•T base pair to a G•C base pair on the PCSK9 gene in mouse liver, demonstrating in vivo CID-controlled DNA base editing. Thus, sABE enables precise control of base editing, which will have broad implications for basic research and in vivo therapeutic applications.
- 11 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessA split and inducible adenine base editor for precise in vivo base editing
DNA base editors use deaminases fused to a programmable DNA-binding protein for targeted nucleotide conversion. However, the most widely used TadA deaminases lack post-translational control in living cells. Here, we present a split adenine base editor (sABE) that utilizes chemically induced dimerization (CID) to control the catalytic activity of the deoxyadenosine deaminase TadA-8e. sABE shows high on-target editing activity comparable to the original ABE with TadA-8e (ABE8e) upon rapamycin induction while maintaining low background activity without induction. Importantly, sABE exhibits a narrower activity window on DNA and higher precision than ABE8e, with an improved single-to-double ratio of adenine editing and reduced genomic and transcriptomic off-target effects. sABE can achieve gene knockout through multiplex splice donor disruption in human cells. Furthermore, when delivered via dual adeno-associated virus vectors, sABE can efficiently convert a single A•T base pair to a G•C base pair on the PCSK9 gene in mouse liver, demonstrating in vivo CID-controlled DNA base editing. Thus, sABE enables precise control of base editing, which will have broad implications for basic research and in vivo therapeutic applications.